SG Americas Securities’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

SG Americas Securities’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-295	Closed	-$78K	–	3316
2022 Q3	$78K	Buy	295 +1	+0.3%	+$381	﹤0.01%	2917
2022 Q2	$131K	Buy	294 +12	+4%	+$8.48K	﹤0.01%	2952
2022 Q1	$349K	Buy	+282	New	+$384K	﹤0.01%	2111
2021 Q4	–	Sell	-49	Closed	-$892K	–	3733
2021 Q3	$892K	Buy	+49	New	+$779K	﹤0.01%	2003
2021 Q2	–	Sell	-116	Closed	-$838K	–	3166
2021 Q1	$838K	Sell	116 -94	-45%	-$676K	﹤0.01%	1668
2020 Q4	$1.17M	Sell	210 -63	-23%	-$558K	0.01%	1456
2020 Q3	$2.73M	Buy	273 +79	+41%	+$718K	0.02%	579
2020 Q2	$1.79M	Buy	194 +176	+978%	+$1.61M	0.01%	908
2020 Q1	$168K	Buy	+18	New	+$178K	﹤0.01%	2632

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

SG Americas Securities's IRLA Position: Q4 2022 in Review

SG Americas Securities sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2022, closing a stake of 295 shares — an estimated $78K sold.

SG Americas Securities first reported a position in IRLA in Q1 2020 and held it in 9 quarters. The position peaked at $2.73M in Q3 2020. 48 funds tracked by Wall St. Rank hold IRLA as of Q4 2022.

SG Americas Securities reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
SG Americas Securities sold 295 IRulya Therapeutics Inc. Common Stock shares in Q4 2022, an estimated $78K.
SG Americas Securities first reported a position in IRulya Therapeutics Inc. Common Stock in Q1 2020 and held it in 9 quarters.
SG Americas Securities's IRulya Therapeutics Inc. Common Stock position peaked at $2.73M in Q3 2020.
48 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2022.

Based on SG Americas Securities's 13F filing for Q4 2022, filed 2 Feb 2023.